Mr. Marcos Agramont reports

ISODIOL INTERNATIONAL INC. FINALIZES SHARE CONSOLIDATION

Further to the company's news release dated June 27, 2018, the consolidated common shares of Isodiol International Inc. at a ratio of one postconsolidated common share for every 10 preconsolidated common shares held will commence trading on the Canadian Securities Exchange on July 24, 2018. The new Cusip number will be 46500L 20 0 and the new ISIN number will be CA 46500L 20 0 3.

Following the consolidation, the company's issued and outstanding common shares will be reduced from 395,803,482 to approximately 39,580,349. Any resulting fractional share entitlement remaining after conversion at 0.5 or over will be rounded up to the nearest whole number and below 0.5 will be rounded down to the nearest whole number.

A letter of transmittal will be sent by mail to registered shareholders on July 27, 2018, advising that the consolidation has taken effect. The letter of transmittal will contain instructions on how registered shareholders can exchange their share certificates and/or DRS statements evidencing their preconsolidated common shares for new share certificates and/or new DRS statements representing the number of postconsolidated common shares to which they are entitled. No action is required by non-registered shareholders (shareholders who hold their shares through an intermediary) to effect the consolidation.

About Isodiol International Inc.

Isodiol International is the market leader in pharmaceutical-grade pure, natural CBD (cannabidiol) and the industry leader in the manufacturing and development of CBD consumer products.

Isodiol is the pioneer of many firsts in the CBD industry, including the commercialization of 99-per-cent-plus pure, natural isolated CBD, microencapsulations and nano-technology for the highest quality consumable and topical skin care products. Most recently, the company received approval for its CBD designated as an active pharmaceutical ingredient for use in finished pharmaceutical products as was announced April 26, 2018.

Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its consumer products portfolio and aggressively continue international expansion into Latin America, Asia and Europe.

We seek Safe Harbor.